Clinical Trial Update: Itacitinib (INCB039110) and Extracorporeal Photopheresis (ECP) for First-Line Treatment in Chronic GVHD [Phase 2]

View source ↗

Summary

Phase 2 trial update for itacitinib (INCB039110) with Extracorporeal Photopheresis in first-line chronic graft-versus-host disease has been terminated with resu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• Extracorporeal Photopheresis
• INCB039110 (Itacitinib)
• Itacitinib (itacitinib)

Snippet

Sponsor: University of Utah | Conditions: Chronic Graft-versus-host-disease | Phase 2 | Status: TERMINATED | Results posted: 2024-01-22